A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Inclusion Criteria: * Adult patients \>= 18 years of age at screening * Diagnosis of diabetes mellitus Type 2 * Glycosylated hemoglobin A1C (HbA1C) \< 10% at screening * Estimated glomerular filtration rate (eGFR) \>=30 and \< 60 mL/min/1.73 m2 * Urinary albumin-to-creatinine ratio (UACR) \>=500 and \< 5000 mg/g * Treatment with either angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for at least three months prior to screening * Women of child-bearing potential using a highly effective birth control method must be willing to use the same method of contraception during the entire course of the study Exclusion Criteria: * Treatment with a PPARgamma agonist and/or PPARalpha agonist in the last 12 weeks screening * Prior intolerance to a TDZ or fibrate * Previous participation in a trial with aleglitazar * Diagnosis or history of other types of diabetes * Diagnosis or history of acute metabolic diabetic complications within the past 6 months * Known primary glomerulonephritis, secondary glomerulonephritis other than diabetic nephropathy or polycystic kidney disease * Diagnosed acute kidney injury or dialysis within 12 weeks prior to screening * Poorly controlled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg at baseline) * Known secondary hypertension due to renal artery stenosis, primary aldosteronism, or pheochromocytoma * History of myocardial infarction or stroke in the past 12 weeks prior to screeni…